anti-CCR7 monoclonal antibody CAP-100

{
  "id": "MLC-T-ONC-010200",
  "term": "anti-CCR7 monoclonal antibody CAP-100",
  "field": "Oncology and biomedicine",
  "definition": "A humanized immunoglobulin G1 (IgG1) monoclonal antibody against C-C-chemokine receptor 7 (CCR7), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR7 monoclonal antibody CAP-100 targets and binds to CCR7 on tumor cells, and neutralizes ligand-mediated signaling through both ligands CCL19 and CCL21. This prevents the activity of CCR7 on tumor cells. CAP-100 is expected to prevent the migration of tumor cells to and their survival in lymphoid niches. In addition, CAP-100 eliminates CCR7-positive tumor cells via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). CCR7, a G-protein coupled receptor involved in trafficking of cells to lymph nodes, is normally expressed by subsets of immune cells and overexpressed in various types of cancer cells, such as in many hematological malignancies. Its overexpression has been associated with lymph node metastasis and poor survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-ccr7-monoclonal-antibody-cap-100/"
}